fbpx Skip to main content

BioCommunique Article

Hear from Dr. Kate Broderick with Inovio Pharmaceuticals, a San Diego company working to help contain COVID-19.

Next Breakfast with Biocom Will Focus on Coronavirus

  • 2020-03-06T20:12:00.000+0000
  • San Diego
  • Author: Ashleigh Farver

Biocom's next Breakfast with Biocom on March 19th in San Diego will feature an exclusive fireside chat with Inovio Pharmaceuticals, a San Diego company fighting to contain the novel coronavirus COVID-19. Hear the latest from Dr. Kate E. Broderick, Senior Vice President R&D Pharmaceuticals and nCoV Project Lead at Inovio Pharmaceuticals.

Dr. Broderick has a broad background in the product development and device development DNA therapeutic and drug delivery field, with specific expertise in in vivo DNA therapeutic animal studies and product development in relation to DNA delivery. Her particular area of focus is infectious diseases with an emphasis on emerging targets and those from a bio-threat potential. On the bio-engineering side, Dr. Broderick leads the device design efforts specifically pertaining to tissue delivery and she has been central to the development of Inovio novel prototypes and designs. Dr. Broderick leads a diverse team of researchers which encompasses early discovery work through to IND enabling studies and she is subsequently involved in the clinical and regulatory development of these products.

Dr. Broderick has authored and co-authored over 70 peer reviewed article and her group regularly publish their findings and present their work in the public forum at conferences. Due to her expertise in the area, Dr. Broderick has been invited to participate in WHO advisory meetings related to DNA vaccines and their delivery. Dr Broderick is also a co-inventor on multiple patents related to DNA vaccine delivery and is principal investigator on grants, awards and contracts from funding bodies such as The Gates Foundation, NIH, Department of Defense and SBIR. She was recently awarded a contract of $56 million from CEPI to fast-track DNA based vaccine candidates for Lassa and MERS through clinical testing.

Dr. Broderick received her PhD from the University of Glasgow in Scotland and performed her post-doctoral research at the University of California, San Diego. She joined Inovio Pharmaceuticals in 2006 where she currently leads a diverse research group focused on enhanced delivery techniques for gene based therapeutics as the Senior Vice President, Preclinical R&D.

Moderator: Li Chen, Vice President and General Manager, Synthetic Biology, Molecular Biology, Thermo Fisher Scientific

Li Chen has 15 years of commercial experience in the biotech industry. She joined Thermo Fisher Scientific in 2011 and was a game changer in transforming China BID business, building a solid infrastructure and strategy map as well as successfully launching eCommerce. She then relocated to Singapore and was responsible for BID business in Asia Pacific Japan.

Prior to this role, Li was the Life Sciences BU leader at Merck Millipore China and Sales & Marketing Director at Sigma Aldrich China. Li received her Bachelor’s degree in Biochemistry from Nanjing University in 1995 and her PhD in 2000 in Molecular Biology & Biochemistry from Shanghai Institute of Biochemistry, Chinese Academy of Sciences. She completed postdoc research at Yale University and University of California, Berkley. Li also completed her EMBA from CEIBS.